Research priorities in biomarkers and surrogate end-points. - Test2 - elhamkhani - TriplyDB

Research priorities in biomarkers and surrogate end-points.

Research priorities in biomarkers and surrogate end-points.

http://www.wikidata.org/entity/Q36081463

about

Pragmatic medicine in solid cancer: a translational alternative to precision medicine The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders Integration of lyoplate based flow cytometry and computational analysis for standardized immunological biomarker discovery.Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations.Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage.Circulating Biomarkers for Duchenne Muscular Dystrophy.MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.Biomarkers-A General Review.Editors' pick 2012.Commentary to "Patients not patents: drug research and development as a public enterprise".Relationship Between Gender and the Effectiveness of Montelukast: An Italian/Danish Register-Based Retrospective Cohort Study

P2860

Q28391863-F01BE4F0-4E68-450E-8CB4-786EBEF19469 Q28543430-2DAA6B6B-ABF9-47B9-8C10-7AC3BD900C0C Q34356779-E80CDFA9-6582-49E4-9872-A3063DF26191 Q35319254-662D6BE6-50DF-4EC6-8F36-769AFE10AB49 Q36677856-EACC579F-4BE7-415A-9B2D-14D73E3278D0 Q37476761-9A99F3D1-F2D3-4775-88AD-C0999166AA36 Q37610530-0C893BB5-2F81-4147-BB1B-BF2B4F6516DE Q38867829-A535DEF5-F005-4383-BB72-384011F369BA Q39183771-15A0C025-6085-4B6D-8D6C-936093EC0184 Q42976095-B9A6DDA8-280F-4645-8EE2-4D3368252158 Q48341652-AA8F5777-11B3-4805-95A7-63CEA5AEFD06 Q58803402-24BC0092-1C3D-4DF8-9AA2-8292E27E749A

P2860

Research priorities in biomarkers and surrogate end-points.

http://www.wikidata.org/entity/Q36081463

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Research priorities in biomarkers and surrogate end-points.

@ast

Research priorities in biomarkers and surrogate end-points.

@en

type

label

Research priorities in biomarkers and surrogate end-points.

@ast

Research priorities in biomarkers and surrogate end-points.

@en

prefLabel

Research priorities in biomarkers and surrogate end-points.

@ast

Research priorities in biomarkers and surrogate end-points.

@en

P1433

Q36081463-435C1750-B842-4747-B0A1-7260F1730803

P1476

Q36081463-4ED6603E-6AF6-47E6-9769-B8B061473274

P2860

Q36081463-2669D3B5-086C-4A5A-AEDF-95F5BB9C15C7

Q36081463-298BCEF1-2B8A-4DD1-ACFA-5270E9280687

Q36081463-29EA169B-4A16-412A-A410-4B5849F9DE36

Q36081463-2A99C824-347B-4399-BD49-AEB19F565AA6

Q36081463-2C5C89E8-BC74-4372-9753-BDE9D4F847EB

Q36081463-4E49E9B9-71D1-4D82-9C34-79D115ADE59F

Q36081463-55A15084-9F50-4D52-A351-8A78A5B06F36

Q36081463-67AEDD31-ADB0-4BEC-B3C2-0F8BA73290F4

Q36081463-74F30401-9CD2-4C41-BE40-ED1929F789B6

Q36081463-77F9FBA4-8A7A-43E1-896F-F13C0A838854

P304

Q36081463-748D03DD-D703-44A1-B730-01128A884806

P31

Q36081463-4AE21322-3FA8-4EF0-B63C-6F87907FD739

P356

Q36081463-58DCFA3B-A926-4635-A192-53F814209202

P407

Q36081463-9B692C84-80BA-4B09-99D5-A3ADF26941F6

P433

Q36081463-70423EA0-251D-4B93-B3AB-7D8C6CCE1CFC

P478

Q36081463-FBF5249B-B426-4582-BFDB-BDAB37B3D283

P50

Q36081463-3BF6D184-2F1C-4756-B360-216BDFB89F14

P577

Q36081463-69DA19EC-D82A-4CE4-A815-A7A388C62293

P5875

Q36081463-2E7FF4D8-3690-4B54-A920-D2A8E9744CDA

P698

Q36081463-8F845D16-D02D-43A3-902B-76782DA49FCF

P921

Q36081463-2C620E8F-D52B-43E1-9FC5-36EC5B32E6E6

P932

Q36081463-2458A0C9-A962-48B9-8A05-3D0AFA9A8CBB

P356

J.1365-2125.2012.04234.X

P1433

British Journal of Clinical Pharmacology

P1476

Research priorities in biomarkers and surrogate end-points.

@en

P2860

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Biomarkers and surrogate endpoints

The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment

Nonresolving or slowly resolving pneumonia.

When can a risk factor be used as a worthwhile screening test?

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Paracetamol overdose: an evidence based flowchart to guide management.

Strategies for developing biomarkers of heart failure.

ABC of monitoring drug therapy. Cyclosporin

Analytic aspects of monitoring therapy with thiopurine medications.

P304

900-907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2012.04234.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Aronson

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221856685

http://www.w3.org/2001/XMLSchema#string

P698

22360291

http://www.w3.org/2001/XMLSchema#string

P921

P932

3391516

http://www.w3.org/2001/XMLSchema#string